Arcus Biosciences (RCUS) Assets Average (2018 - 2026)

Arcus Biosciences' Assets Average history runs 9 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 9.11% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 9.11% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 1.96% from the prior year.
• Assets Average advanced to $1.1 billion in Q1 2026 per RCUS's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.6 billion in Q1 2022 and bottomed at $1.0 billion in Q3 2025.
• The 5-year median for Assets Average is $1.2 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Assets Average surged 83.64% in 2022 and decreased 18.54% in 2023, its largest moves.
• Year by year, Assets Average stood at $1.3 billion in 2022, then dropped by 15.14% to $1.1 billion in 2023, then rose by 7.17% to $1.2 billion in 2024, then fell by 13.76% to $1.1 billion in 2025, then advanced by 1.09% to $1.1 billion in 2026.
• Per Business Quant, the three latest RCUS Assets Average figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025).